{"generic":"Dulaglutide","drugs":["Dulaglutide","Trulicity"],"mono":{"0":{"id":"jyels0","title":"Generic Names","mono":"Dulaglutide"},"1":{"id":"jyels1","title":"Dosing and Indications","sub":[{"id":"jyels1b4","title":"Adult Dosing","mono":"<b>Type 2 diabetes mellitus, Adjunct to diet and exercise:<\/b> initial dose, 0.75 mg SUBQ once weekly; may be increased to MAX of 1.5 mg SUBQ once weekly "},{"id":"jyels1b5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"jyels1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment (including ESRD):<\/b> no dose adjustment recommended; use caution when initiating therapy or titrating upward<\/li><li><b>hepatic impairment:<\/b> use with caution<\/li><li><b>concomitant use with insulin or insulin secretagogues:<\/b> consider reducing insulin or insulin secretagogue dose<\/li><\/ul>"},{"id":"jyels1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Type 2 diabetes mellitus, Adjunct to diet and exercise<br\/>"}]},"2":{"id":"jyels2","title":"Black Box Warning","mono":"<b>Subcutaneous (Solution)<\/b><br\/>Dulaglutide caused thyroid C-cell tumors in rats, that was related to dose and duration of treatment. However, it is unknown if dulaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Dulaglutide is contraindicated in patients who have a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2. The value of monitoring calcitonin levels or thyroid ultrasound routinely is uncertain.<br\/>"},"3":{"id":"jyels3","title":"Contraindications\/Warnings","sub":[{"id":"jyels3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to dulaglutide or any of its components<\/li><li>multiple endocrine neoplasia syndrome type 2 or personal or family history of medullary thyroid carcinoma<\/li><\/ul>"},{"id":"jyels3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- thyroid C-cell tumors have been reported in rats; it is unknown if thyroid C-cell tumors may occur in humans<\/li><li>Gastrointestinal:<\/li><li>-- pancreatitis has been reported; monitor for signs and symptoms, and permanently discontinue if confirmed<\/li><li>-- severe gastrointestinal adverse reactions may occur; not recommended in patients with severe gastrointestinal disease, including severe gastroparesis<\/li><li>Renal:<\/li><li>-- acute renal failure and worsening of chronic renal failure have been reported, especially with nausea, vomiting, diarrhea or dehydration; in patients with renal impairment, use caution when starting or adjusting dosage and monitor renal function with severe adverse gastrointestinal reactions<\/li><\/ul>"},{"id":"jyels3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jyels3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jyels4","title":"Drug Interactions","sub":{"1":{"id":"jyels4b14","title":"Major","mono":"<ul><li>Acetohexamide (established)<\/li><li>Amisulpride (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Chlorpropamide (established)<\/li><li>Clozapine (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Gliclazide (established)<\/li><li>Glimepiride (established)<\/li><li>Glipizide (established)<\/li><li>Gliquidone (established)<\/li><li>Glyburide (established)<\/li><li>Iloperidone (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Lanreotide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tolazamide (established)<\/li><li>Tolbutamide (established)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},"2":{"id":"jyels4b15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Esmolol (probable)<\/li><li>Furazolidone (probable)<\/li><li>Insulin (probable)<\/li><li>Insulin Aspart, Recombinant (probable)<\/li><li>Insulin Bovine (probable)<\/li><li>Insulin Degludec (probable)<\/li><li>Insulin Detemir (probable)<\/li><li>Insulin Glulisine (probable)<\/li><li>Insulin Lispro, Recombinant (probable)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Labetalol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Linezolid (probable)<\/li><li>Methylene Blue (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moclobemide (probable)<\/li><li>Nadolol (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nialamide (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Phenelzine (probable)<\/li><li>Pindolol (probable)<\/li><li>Practolol (probable)<\/li><li>Procarbazine (probable)<\/li><li>Propranolol (probable)<\/li><li>Rasagiline (probable)<\/li><li>Selegiline (probable)<\/li><li>Sotalol (probable)<\/li><li>Timolol (probable)<\/li><li>Tranylcypromine (probable)<\/li><\/ul>"}}},"5":{"id":"jyels5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Abdominal pain (6.5% to 9.4%), Decrease in appetite (4.9% to 8.6%), Diarrhea (8.9% to 12.6%), Nausea (12.4% to 21.1%), Vomiting (6% to 12.7%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrioventricular block, First degree (1.7% to 2.3%)<\/li><li><b>Endocrine metabolic:<\/b>Hypoglycemia (2.6% to 85%), Malignant tumor of thyroid gland<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (0.5%)<\/li><li><b>Renal:<\/b>Acute renal failure, Chronic renal failure, Exacerbation<\/li><\/ul>"},"6":{"id":"jyels6","title":"Drug Name Info","sub":{"0":{"id":"jyels6b17","title":"US Trade Names","mono":"Trulicity<br\/>"},"2":{"id":"jyels6b19","title":"Class","mono":"<ul><li>Antidiabetic<\/li><li>Glucagon-Like Peptide-1 Receptor Agonist<\/li><\/ul>"},"3":{"id":"jyels6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jyels6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jyels7","title":"Mechanism Of Action","mono":"Dulaglutide is a glucagon-like peptide (GLP-1) receptor agonist. Insulin release is stimulated in a glucose-dependent manner via activation of GLP-1 receptors on pancreatic beta cells. Glucagon secretion is also reduced and gastric emptying is delayed.<br\/>"},"8":{"id":"jyels8","title":"Pharmacokinetics","sub":[{"id":"jyels8b23","title":"Absorption","mono":"<ul><li>Tmax, subQ: 48 hours<\/li><li>Bioavailability, subQ: 47% to 65%<\/li><\/ul>"},{"id":"jyels8b24","title":"Distribution","mono":"Vd: 17.4 to 19.2 L <br\/>"},{"id":"jyels8b25","title":"Metabolism","mono":"degradation by protein catabolism presumed <br\/>"},{"id":"jyels8b26","title":"Excretion","mono":"Total body clearance: 0.107 to 0.111 L\/hr <br\/>"},{"id":"jyels8b27","title":"Elimination Half Life","mono":"5 days <br\/>"}]},"9":{"id":"jyels9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>do not mix with other antidiabetic agents in same syringe<\/li><li>administer separately from insulin; may be administered in the same body region but not in adjacent sites<\/li><li>inject subQ into the abdomen, thigh, or upper arm and rotate sites each week<\/li><li>do not administer IM or IV<\/li><li>administer missed dose if at least 72 hours until next scheduled dose, and administer next scheduled dose on regularly scheduled day; if next scheduled dose less than 72 hours away, skip missed dose and administer on next scheduled dose day<\/li><\/ul>"},"10":{"id":"jyels10","title":"Monitoring","mono":"<ul><li>improved type 2 diabetes glycemic control is indicative of efficacy.<\/li><li>renal function, in patients with renal impairment who report severe gastrointestinal reactions<\/li><li>blood glucose and HbA1c levels, periodically during diabetic therapy<\/li><li>signs and symptoms of pancreatitis, after treatment initiation<\/li><\/ul>"},"11":{"id":"jyels11","title":"How Supplied","mono":"<b>Trulicity<\/b><br\/>Subcutaneous Solution: 0.75 MG\/0.5 ML, 1.5 MG\/0.5 ML<br\/>"},"13":{"id":"jyels13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient to report symptoms of pancreatitis or renal failure.<\/li><li>Advise patient to report hypoglycemia if used with insulin or a sulfonylurea.<\/li><li>Side effects may include decreased appetite, nausea, abdominal pain, diarrhea, or vomiting.<\/li><li>Instruct patient to report symptoms of a thyroid tumor.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Tell patient to maintain adequate hydration.<\/li><li>Instruct patient to take a missed dose as soon as possible if there are at least 3 days (72 hours) before the next scheduled dose, but if less than 3 days remain skip the missed dose.<\/li><\/ul>"}}}